Showing 2741-2750 of 5771 results for "".
- EyeDura's Sustained-Release Eye Drop Technology Wins Industry Honorshttps://modernod.com/news/eyeduras-sustained-release-eye-drop-technology-wins-industry-honors/2482886/EyeDura Therapeutics, developer of preservative-free sustained release ophthalmic therapies, announced it received top recognition at two major industry forums among a field of ophthalmic startup companies. EyeDura won 'The Winning Pitch' challeng
- AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into Phase 1/2 Clinical Trialhttps://modernod.com/news/aavantgarde-receives-fda-clearance-to-progress-stargardt-disease-asset-aavb-039-into-phase-12-clinical-trial/2482885/AAVantgarde Bio announced that the FDA has cleared its investigational new drug (IND) application for AAVB-039, the company’s gene therapy program for Stargardt disease. AAVantgarde is now initiating CELESTE, a first-in-human phase 1/2 clinical trial in the United States to e
- Nanoscope Initiates Rolling Submission of BLA to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat RPhttps://modernod.com/news/nanoscope-initiates-rolling-submission-of-bla-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-rp/2482884/Nanoscope Therapeutics announced the initiation of a rolling submission of a biologics license application (BLA) to the FDA for its lead investigational therapy, MCO-010, for the treatment of severe vision loss due to retinitis pigmentosa (RP). This marks a significant re
- Alcon Receives Health Canada Approval for Unity VCShttps://modernod.com/news/alcons-receives-health-canada-approval-for-unity-vcs/2482882/Alcon announced that Unity Vitreoretinal Cataract System (VCS) has received Health Canada approval. Unity VCS is designed to deliver enhanced workflow efficiencies over Alcon’s current leading systems, Constellation Vision System for vitreoretinal and combined proce
- Johnson & Johnson Appoints Kelly Heaps, Vice President of US Sales, Vision Carehttps://modernod.com/news/johnson-johnson-appoints-kelly-heaps-vice-president-of-us-sales-vision-care/2482879/Johnson & Johnson announced the appointment of Kelly Heaps as Vice President of US Sales, Vision Care. As the leader of the US Sales Organization, Ms. Heaps will work to accelerate sales and foster market share growth while collaborating with customers to strengthen patient outcomes.
- Beacon Therapeutics Completes Enrollment in Registrational Phase 2/3 VISTA Trial of laru-zova for Patients with XLRPhttps://modernod.com/news/beacon-therapeutics-completes-enrollment-in-registrational-phase-23-vista-trial-of-laru-zova-for-patients-with-xlrp-1/2482875/Beacon Therapeutics announced it has completed enrollment in its registrational phase 2/3 VISTA trial evaluating laru-zova for the treatment of X-linked retinitis pigmentosa (XLRP). The study enrolled eligible male patients aged 12 to 50 across sites in North America, the United Kingdom
- First Patient Dosed in the Phase 1 Trial of PulseSight Therapeutics’ Investigational PST-611 Treatment for Dry AMD/GAhttps://modernod.com/news/first-patient-dosed-in-the-phase-1-trial-of-pulsesight-therapeutics-investigational-pst-611-treatment-for-dry-amdga/2482874/PulseSight Therapeutics has announced that the first patient has been dosed in its phase 1 clinical trial (PST-611-CT1) assessing the safety and tolerability of its lead program, PST-611, in humans. PST-611 is a first-in-class non-viral vectorized
- Alcon to Acquire LumiThera, Maker of Photobiomodulation Device for the Treatment of Dry AMDhttps://modernod.com/news/alcon-to-acquire-lumithera-maker-of-photobiomodulation-device-for-the-treatment-of-dry-amd/2482873/In a move to bolster is vitreoretinal surgery portfolio, Alcon announced its intention to acquire LumiThera and its photobiomodulation (PBM) device for the treatment of dry early and intermediate dry AMD.
- Bausch + Lomb Launches Dry Eye Education Campaignhttps://modernod.com/news/bausch-lomb-launches-dry-eye-education-campaign/2482872/Bausch + Lomb announced the launch of “Eyes Tell the Story: The Impact of Dry Eye,” a new awareness campaign designed to spotlight the burden of dry eye symptoms through storytelling, photography, and insights from the company’s latest nationw
- Formycon and Bio Usawa Partner Bio to Provide FYB201/ BioUcenta (Ranibizumab) Across Sub-Saharan Africahttps://modernod.com/news/formycon-and-bio-usawa-partner-bio-to-provide-fyb201-bioucenta-ranibizumab-across-sub-saharan-africa/2482870/Formycon announced a partnership between Bioeq AG—licensee and exclusive global commercialization rights holder for Formycon’s biosimilar FYB201—and African biotechnology company Bio Usawa Biotechnology. The agreement grants Bio Usawa exclusiv